Cent Eur J Public Health 2022, 30(Supplement):S11-S15 | DOI: 10.21101/cejph.a6807
Prostate cancer screening - is it time to change approach?
- 1 Urological Outpatient Clinic, Railway Hospital, Košice, Slovak Republic
- 2 Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
- 3 Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic
Objective: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options.
Methods: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated.
Results: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients.
Conclusion: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.
Keywords: prostate cancer management, quality of life, conservative treatment, prostate cancer, prevention and health promotion
Received: February 20, 2021; Revised: January 3, 2022; Accepted: January 3, 2022; Published: June 27, 2022 Show citation
References
- Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164-87.
Go to original source...
Go to PubMed...
- Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RCN, Bangma CH, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79-85.
Go to original source...
Go to PubMed...
- Hugosson J. Stopping screening, when and how? Transl Androl Urol. 2018;7(1):46-53.
Go to original source...
Go to PubMed...
- Heijnsdijk EAM, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst. 2015;107(1):366. doi: 10.1093/jnci/dju366.
Go to original source...
Go to PubMed...
- White MC, Hayes NS, Richardson LC. Public health's future role in cancer survivorship. Am J Prev Med. 2015;49(6 Suppl 5):S550-3.
Go to original source...
Go to PubMed...
- Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108(10):djw110. doi: 10.1093/jnci/djw110.
Go to original source...
Go to PubMed...
- Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 2007;23(7):455-68.
Go to original source...
Go to PubMed...
- Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel: Consensus panel report on TRUS in focal therapy of prostate cancer. BJU Int. 2012;110(7):942-8.
Go to original source...
Go to PubMed...
- Ondrušová M, Ondruš D. Trends in prostate cancer epidemiology in Slovakia - an international comparison. Klin Onkol. 2017;30(2):115-20.
Go to original source...
Go to PubMed...
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Go to original source...
Go to PubMed...
- Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL Jr, Freedland SJ. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2936-42.
Go to original source...
Go to PubMed...
- Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study). Eur Urol. 2019;76(6):790-813.
Go to original source...
Go to PubMed...
- Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, et al. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52(1):27-37.
Go to original source...
Go to PubMed...
- Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
Go to original source...
Go to PubMed...
- Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43-51.
Go to original source...
Go to PubMed...
- Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
Go to original source...
Go to PubMed...
- Osses DF, Remmers S, Schröder FH, van der Kwast T, Roobol MJ. Results of prostate cancer screening in a unique cohort at 19yr of follow-up. Eur Urol. 2019;75(3):374-7.
Go to original source...
Go to PubMed...
- Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine (Baltimore). 2018;97(13):e0249. doi: 10.1097/MD.0000000000010249.
Go to original source...
Go to PubMed...
- Patil SR, Pawar PW, Sawant AS, Patil AV, Narwade SS, Mundhe ST, et al. TRUS biopsy yield in Indian population: A retrospective analysis. J Clin Diagn Res. 2017;11(2):PC01-5. doi: 10.7860/JCDR/2017/25473.9251.
Go to original source...
Go to PubMed...
- Zhang M, Milot L, Khalvati F, Sugar L, Downes M, Baig SM, et al. Value of increasing biopsy cores per target with cognitive MRI-targeted transrectal US prostate biopsy. Radiology. 2019;291(1):83-9.
Go to original source...
Go to PubMed...
- Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on Prostate Cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-55.
Go to original source...
Go to PubMed...
- Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, et al. Screening for familial and hereditary prostate cancer: screening in prostate cancer families. Int J Cancer. 2016;138(11):2579-91.
Go to original source...
Go to PubMed...
- Bell KJL, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749-57.
Go to original source...
Go to PubMed...
- Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16(1):845. doi: 10.1186/s12885-016-2891-z.
Go to original source...
Go to PubMed...
- Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66(6):1054-64.
Go to original source...
Go to PubMed...